România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

omega pharma international nv - belgia - combinatii (paracetamolum+acidum ascorbicum+phenylephrinum) - pulb. pt. sol. orala - 1000mg+70mg+10mg - alte analgezice si antipiretice anilide (inclusiv combinatii)

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

omega pharma international nv - belgia - combinatii (paracetamolum+acidum ascorbicum+phenylephrinum) - pulb. pt. susp. orala - 1000mg/40mg/10mg - alte analgezice si antipiretice anilide (inclusiv combinatii)

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

wrafton laboratories ltd. - marea britanie - combinatii - sirop - alte analgezice si antipiretice anilide (inclusiv combinatii)

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

actavis ltd. - malta - combinatii (telmisartanum+hydrochlorothiazidum) - compr. - 40mg/12,5mg - antagonisti ai angiotensinaei ii, combinatii antagonisti ai angiotensin ii si diuretic

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

actavis ltd. - malta - combinatii (telmisartanum+hydrochlorothiazidum) - compr. - 80mg/12,5mg - antagonisti ai angiotensinaei ii, combinatii antagonisti ai angiotensin ii si diuretic

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

actavis ltd. - malta - combinatii (telmisartanum+hydrochlorothiazidum) - compr. - 80mg/25mg - antagonisti ai angiotensinaei ii, combinatii antagonisti ai angiotensin ii si diuretic

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

accord healthcare polska sp. z.o.o. - polonia - paracetamolum - compr. eff. - 1000mg - alte analgezice si antipiretice anilide (inclusiv combinatii)

Uniunea Europeană - română - EMA (European Medicines Agency)

yes pharmaceutical development services gmbh - doxorubicină clorhidrat - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - agenți antineoplazici - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).

Uniunea Europeană - română - EMA (European Medicines Agency)

pfizer europe ma eeig - ritlecitinib tosilate - alopecia areata - imunosupresoare - litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.

Uniunea Europeană - română - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - cedazuridine, decitabine - leucemie mieloidă - agenți antineoplazici - inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for standard induction chemotherapy.